COMMUNIQUÉS West-GlobeNewswire

IBA – ACQUISITION D’ACTIONS PROPRES
10/02/2026
Louvain-la-Neuve, Belgique, 10 février 2026 – 18h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") [...]
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 31 janvier 2026
10/02/2026
Nombre total de droits de vote et d’actions composant le capital social au 31 janvier 2026 (Conformément à l’article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l’AMF) Paris, [...]
Press Release: Sanofi completes the acquisition of Dynavax
10/02/2026
Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition includes Dynavax’s adult [...]
MedWell Ai Executes Letter Of Intent To Create America's First Vertically Integrated Regenerative Wellness Eco-System
10/02/2026
CLEARWATER, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- via IBN – MedWell Ai, Inc ("Company") (OTCQB: MWAI) is pleased to announce the signing of a Letter of Intent (“LOI”) to create a vertically integrated health, wellness [...]
BioCardia Files Pre-Submission for FDA Approval of Helix™ Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the Heart
10/02/2026
SUNNYVALE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported it [...]
Communiqué de presse : Sanofi finalise l’acquisition de Dynavax
10/02/2026
Sanofi finalise l’acquisition de Dynavax Paris, le 10 février 2026. Sanofi a annoncé aujourd’hui avoir finalisé l’ acquisition de Dynavax Technologies Corporation (Dynavax). L’acquisition comprend le vaccin contre l’ [...]
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of January 31, 2026
10/02/2026
Disclosure of Share Capital and Voting Rights Outstanding as of January 31, 2026 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]
IBA – ACQUISITION OF OWN SHARES
10/02/2026
Louvain-la-Neuve, Belgium, February 10 th , 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA [...]
Hyagen Medical Launches National FDA Compliance and Education Initiative to Strengthen Regenerative Medicine Standards
10/02/2026
FDA-aligned education and compliance for ethical stem cell and regenerative medicine practices Lehi, UT, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Hyagen Medical , a regulatory compliance and education company specializing in [...]
Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline
10/02/2026
WHO recognition of “etaroleucel” (CELZ-101) builds on prior “olastrocel” (CELZ-201) milestone, reinforcing platform credibility and supporting multi-program execution PHOENIX, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Creative [...]
Tecan to host Analyst and Media Conference with Capital Markets Update on March 16, 2026
10/02/2026
Männedorf, Switzerland, February 10, 2026 – The Tecan Group (SIX Swiss Exchange: TECN) will hold an Analyst and Media Conference on Monday, March 16, 2026, at 2:00 pm CET to present its full-year 2025 financial results [...]
Hassan Spine & Sports Medicine Rebrands as NefraHealth
10/02/2026
New Identity Reflects Patient-First Philosophy, Practice Growth Board-Certified Spine Surgeon Joins Growing Central Jersey Practice OLD BRIDGE, N.J., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Hassan Spine & Sports Medicine [...]
Exousia Pro, Inc. Accelerates Strategic Expansion with Third Telehealth Acquisition; Strengthens Pathway to Low-Cost Customer Acquisition
10/02/2026
ORLANDO, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Exousia Pro, Inc. (OTCID: MAJI) , a clinical-stage biotechnology company specializing in proprietary exosome-based delivery systems, is pleased to announce a significant [...]
BioAro Secures UAE Approval for AI-Enabled Longevity Bioactives, Setting the Stage for Global Expansion
10/02/2026
DUBAI, United Arab Emirates and TORONTO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- BioAro Inc. , a biotechnology company at the forefront of precision health and longevity, has achieved a major milestone with regulatory [...]
Repligen to Report Fourth Quarter and Full Year 2025 Financial Results
10/02/2026
Webcast and Conference Call to Be Held Tuesday, February 24, 2026, at 8:30 a.m. ET WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its [...]
Hans Schambye Appointed as Chief Executive Officer of BOOST Pharma
10/02/2026
Advancing development of lead candidate BT-101, a potential disease-modifying treatment for Brittle Bone Disease Preparing for Phase III development following promising data showing reduced fractures in affected [...]
Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting
10/02/2026
WALTHAM, Mass. and BOULDER, Colo., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today [...]
OraSure to Launch OraQuick™ HIV Self-Test in Canada
10/02/2026
BETHLEHEM, Pa., Feb. 10, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its OraQuick [...]
IRADIMED CORPORATION Reports Record Fourth Quarter and Full Year of 2025 Financial Results and Increases its Regular Quarterly Cash Dividend to $0.20 Per Share from $0.17 Per Share
10/02/2026
Reports record revenue of $22.7 million for the fourth quarter of 2025, an increase of $3.3 million, or 17%, compared to the same period in 2024. Reports record GAAP diluted EPS of $0.50 and non-GAAP diluted EPS of $0. [...]

Pages